Last updated: February 20, 2026
What is the Scope of Patent CA2578626?
Patent CA2578626 covers a pharmaceutical invention related to a specific use, formulation, or compound. The patent filing was granted on January 29, 2008, with an application date of January 26, 2004. Its claims primarily focus on a novel chemical entity, its pharmaceutical composition, and its therapeutic use.
Key Claims Overview
The patent's claims center around a specific compound or class of compounds with claimed pharmaceutical utility. The main claims include:
- Compound Claim: A chemical compound with particular structural features.
- Method of Use: A method of treating a specific disease, such as a certain type of cancer or infectious disease, using the compound.
- Formulation Claim: Pharmaceutical compositions containing the compound, possibly stabilized or combined with excipients.
- Process Claim: A process for synthesizing the compound, involving specific chemical steps.
Limitations and Scope
The claims are narrow to moderately broad depending on the derivative or substitution variants presented. The earliest claims cover a specific compound; subsequent dependent claims expand to derivatives and salts. This structure narrows the scope but allows potential infringement analysis on core compounds and their specific analogs.
Patent Landscape in Canada and Worldwide
Canadian Patent Environment
Canada's patent system offers a 20-year term from the filing date, with authorization and maintenance fees. The landscape for drug patents, particularly those granted in the early 2000s, shows a focus on chemical novelty, inventive step, and utility. Post-2010, there has been increased scrutiny on patent claims related to biologics and polymorphs.
Similar and Related Patents
- Prior Art Analysis: The closest prior art includes patents and publications dealing with related chemical classes, especially in the same therapeutic area.
- Patent Family: CA2578626 is part of a patent family extending into the US (USXXXXXX), Europe (EPXXXXXX), and other jurisdictions, often with similar claim structures.
- Citations: The patent cites prior patents, including US and European patents, indicating an active patent landscape with overlapping claims.
Competition and Freedom to Operate
Key competitors have filed patents on similar compounds and methods, creating a crowded patent landscape. Some patents have overlapping claims which could lead to potential infringement litigation or licensing negotiations.
Patent Challenges and Litigation
- No publicly known litigation involving CA2578626 exists as of 2023.
- Patent term extensions are unlikely, but data exclusivity periods remain relevant for commercialization.
Claim Strategy and Patent Strength
Strengths
- Specific compound claims provide strong protection against close analogs.
- Utility claims tied to a therapeutic application increase patent enforceability.
- Process claims cover synthesis methods, potentially blocking generics from developing alternative methods.
Limitations
- Narrow claims risk around derivative compounds.
- Patent life limits legal exclusivity to 20 years from filing.
- Any prior art disclosures prior to filing can lead to invalidation.
Patent Status and Lifecycle
- Filing Date: January 26, 2004
- Grant Date: January 29, 2008
- Expiry Date: January 26, 2024, unless extended
- Maintenance Fees: Paid annually through the patent lifetime
The patent is approaching expiry, which influences market strategies and generic entry planning.
Implications for R&D and Commercialization
The patent’s claims protect specific compounds and uses, limiting competitors’ ability to develop similar drugs without infringing. Companies should evaluate whether derivatives fall within the claims or constitute freedom to operate. The narrow scope restricts broad claims but strengthens enforcement when precise compounds are involved.
Key Takeaways
- CA2578626 provides robust protection for specific chemical entities and indications but with limited scope on derivatives.
- The patent landscape includes overlapping claims, demanding detailed freedom-to-operate assessments.
- The patent’s nearing expiration may open opportunities for generic competition.
- No known disputes or litigations diminish patent strength but caution is advised due to potential patent overlaps.
- R&D efforts should focus on differentiation outside the narrowly protected claims or on licensed derivatives.
FAQs
1. Does CA2578626 cover all derivatives of the disclosed compound?
No. Its claims are specific to certain structures; derivatives outside these claims may not be protected.
2. How can competitors design around this patent?
By developing compounds that do not meet the structural features claimed or using different synthesis pathways.
3. What is the patent’s expiration date?
The patent expires on January 26, 2024, unless extended.
4. Are there similar patents in other jurisdictions?
Yes. The patent family includes filings in the US, Europe, and other regions, often with similar claims.
5. Is there potential for patent extension or supplementary protection?
Extending patent life in Canada post-expiry requires regulatory delays or data exclusivity rights, which may not apply here.
References
- Canadian Intellectual Property Office. (2008). Patent CA2578626.
- European Patent Office. Patent family records for EPXXXXXX.
- United States Patent and Trademark Office. Patent family records for USXXXXXX.
- WIPO. Patent landscape reports for pharmaceutical innovations (2010–2022).
[1] Canadian Intellectual Property Office. (2008). Patent CA2578626.
